Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) EBITDA Margin (2016 - 2026)

Champions Oncology has reported EBITDA Margin over the past 17 years, most recently at 1.67% for Q1 2026.

  • Quarterly results put EBITDA Margin at 1.67% for Q1 2026, down 2807.0% from a year ago — trailing twelve months through Jan 2026 was 4.53% (down 1526.0% YoY), and the annual figure for FY2025 was 8.0%, up 2266.0%.
  • EBITDA Margin for Q1 2026 was 1.67% at Champions Oncology, down from 1.23% in the prior quarter.
  • Over the last five years, EBITDA Margin for CSBR hit a ceiling of 26.4% in Q1 2025 and a floor of 21.44% in Q1 2024.
  • Median EBITDA Margin over the past 5 years was 2.07% (2022), compared with a mean of 4.5%.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 4785bps in 2025 and later crashed -2807bps in 2026.
  • Champions Oncology's EBITDA Margin stood at 0.05% in 2022, then plummeted by -34564bps to 16.89% in 2023, then soared by 132bps to 5.43% in 2024, then plummeted by -77bps to 1.23% in 2025, then crashed by -235bps to 1.67% in 2026.
  • The last three reported values for EBITDA Margin were 1.67% (Q1 2026), 1.23% (Q4 2025), and 3.77% (Q3 2025) per Business Quant data.